ID

29111

Description

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT00642538

Link

https://clinicaltrials.gov/show/NCT00642538

Keywords

Versions (1)
  1. 2/26/18 2/26/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 26, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes Mellitus, Type 2 NCT00642538

English

Eligibility Diabetes Mellitus, Type 2 NCT00642538

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
non-smoking males and females between 18 and 70 years of age
Description

Non-smoker | Age

Data type

boolean

Alias
UMLS CUI [1]
C0337672
UMLS CUI [2]
C0001779
body mass index (bmi) of < 32 kg/m2
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
diabetes managed on a stable regimen of diet and exercise within the preceding 8 weeks and/or metformin and/or a sulfonylurea or meglitinide or alpha glucosidase inhibitors, without any dose adjustments within the preceding 8 weeks. for subjects taking both metformin and sulfonylurea or meglitinide or alpha glucosidase inhibitor, one or both oral agents must be less than 1/2 the maximal allowable dose as cited in the product label.
Description

Diabetes mellitus management | Diet therapy Stable | Exercise Stable | Metformin | Sulfonylurea | Meglitinide | alpha-Glucosidase Inhibitors | Dose Adjustment Absent

Data type

boolean

Alias
UMLS CUI [1]
C0948092
UMLS CUI [2,1]
C0012159
UMLS CUI [2,2]
C0205360
UMLS CUI [3,1]
C0015259
UMLS CUI [3,2]
C0205360
UMLS CUI [4]
C0025598
UMLS CUI [5]
C0038766
UMLS CUI [6]
C0065880
UMLS CUI [7]
C1299007
UMLS CUI [8,1]
C2826232
UMLS CUI [8,2]
C0332197
hba1c = 6.2 to = 8.5%. fasting c-peptide = 0.5 ng/ml. on the last 3 days of the washout period (day -3, -2, and -1) subjects should have a fbg (finger stick) = 13.5 mmol/l.
Description

Glucohemoglobin measurement | Fasting C-peptide level | Fasting blood glucose measurement Washout Period Fingerstick

Data type

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2]
C2208720
UMLS CUI [3,1]
C0428568
UMLS CUI [3,2]
C1710661
UMLS CUI [3,3]
C2022094
normal pulmonary function and performance on pulmonary function tests
Description

Pulmonary function | Pulmonary function tests

Data type

boolean

Alias
UMLS CUI [1]
C0231921
UMLS CUI [2]
C0024119
written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
treatment with any type of anti-diabetic therapy other than metformin, sulfonylurea, meglitinide and alpha glucosidase inhibitors within the preceding 12 weeks [ie, thiazolidinediones (tzds), dipeptyl peptidase inhibitors (dpp-iv), symlin (pramlintide acetate) and or byetta (exenatide)].
Description

Antidiabetics | Exception Metformin | Exception Sulfonylurea | Exception Meglitinide | Exception alpha-Glucosidase Inhibitors | Thiazolidinediones | Dipeptidyl-Peptidase IV Inhibitors | Symlin | pramlintide acetate | Byetta | exenatide

Data type

boolean

Alias
UMLS CUI [1]
C0935929
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0038766
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0065880
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1299007
UMLS CUI [6]
C1257987
UMLS CUI [7]
C1827106
UMLS CUI [8]
C1174780
UMLS CUI [9]
C1174779
UMLS CUI [10]
C1636686
UMLS CUI [11]
C0167117
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
exposure to any investigational medications or devices within the previous 90 days prior to trial entry or participation in another clinical trial while participating in this trial.
Description

Exposure to Investigational New Drugs | Exposure to Investigational Medical Device | Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C2346570
UMLS CUI [3]
C2348568
use of any prescription medication within 90 days prior to screening, other than allowed anti-diabetic therapy, that has not been approved by the pi and sponsor. the use of alpha blockers, antihypertensives, proton pump inhibitors and cholesterol medication as co-medications is allowed throughout the study.
Description

Prescription Drugs | Exception Antidiabetics | Adrenergic alpha-Antagonists allowed | Antihypertensive Agents allowed | Proton Pump Inhibitors allowed | Cholesterol lowering drugs allowed

Data type

boolean

Alias
UMLS CUI [1]
C0304227
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0935929
UMLS CUI [3,1]
C0001641
UMLS CUI [3,2]
C0683607
UMLS CUI [4,1]
C0003364
UMLS CUI [4,2]
C0683607
UMLS CUI [5,1]
C0358591
UMLS CUI [5,2]
C0683607
UMLS CUI [6,1]
C0003277
UMLS CUI [6,2]
C0683607
significant improvement in pre- to post-bronchodilator spirometry (defined as an increase of 12% and 200 ml in either fvc or fev1).
Description

Improvement Spirometry, before and after bronchodilator | FVC Increase | FEV1 Increase

Data type

boolean

Alias
UMLS CUI [1,1]
C2986411
UMLS CUI [1,2]
C0545456
UMLS CUI [2,1]
C3714541
UMLS CUI [2,2]
C0442805
UMLS CUI [3,1]
C0849974
UMLS CUI [3,2]
C0442805
serum creatinine above upper limit of normal (uln) as defined by the laboratory
Description

Serum creatinine raised

Data type

boolean

Alias
UMLS CUI [1]
C0700225
any other condition which, in the opinion of the pi, makes the subject unsuitable for the clinical trial, or could limit the validity of the informed consent and/or impair the subject's ability to participate in the trial.
Description

Condition Study Subject Participation Status Inappropriate | Condition Validity Informed Consent Limited | Condition Study Subject Participation Status Impaired

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1548788
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C2349101
UMLS CUI [2,3]
C0021430
UMLS CUI [2,4]
C0439801
UMLS CUI [3,1]
C0348080
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C0221099
Back to the top of the page

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT00642538

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-smoker | Age
Item
non-smoking males and females between 18 and 70 years of age
boolean
C0337672 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Body mass index
Item
body mass index (bmi) of < 32 kg/m2
boolean
C1305855 (UMLS CUI [1])
Diabetes mellitus management | Diet therapy Stable | Exercise Stable | Metformin | Sulfonylurea | Meglitinide | alpha-Glucosidase Inhibitors | Dose Adjustment Absent
Item
diabetes managed on a stable regimen of diet and exercise within the preceding 8 weeks and/or metformin and/or a sulfonylurea or meglitinide or alpha glucosidase inhibitors, without any dose adjustments within the preceding 8 weeks. for subjects taking both metformin and sulfonylurea or meglitinide or alpha glucosidase inhibitor, one or both oral agents must be less than 1/2 the maximal allowable dose as cited in the product label.
boolean
C0948092 (UMLS CUI [1])
C0012159 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
C0015259 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0025598 (UMLS CUI [4])
C0038766 (UMLS CUI [5])
C0065880 (UMLS CUI [6])
C1299007 (UMLS CUI [7])
C2826232 (UMLS CUI [8,1])
C0332197 (UMLS CUI [8,2])
Glucohemoglobin measurement | Fasting C-peptide level | Fasting blood glucose measurement Washout Period Fingerstick
Item
hba1c = 6.2 to = 8.5%. fasting c-peptide = 0.5 ng/ml. on the last 3 days of the washout period (day -3, -2, and -1) subjects should have a fbg (finger stick) = 13.5 mmol/l.
boolean
C0202054 (UMLS CUI [1])
C2208720 (UMLS CUI [2])
C0428568 (UMLS CUI [3,1])
C1710661 (UMLS CUI [3,2])
C2022094 (UMLS CUI [3,3])
Pulmonary function | Pulmonary function tests
Item
normal pulmonary function and performance on pulmonary function tests
boolean
C0231921 (UMLS CUI [1])
C0024119 (UMLS CUI [2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Antidiabetics | Exception Metformin | Exception Sulfonylurea | Exception Meglitinide | Exception alpha-Glucosidase Inhibitors | Thiazolidinediones | Dipeptidyl-Peptidase IV Inhibitors | Symlin | pramlintide acetate | Byetta | exenatide
Item
treatment with any type of anti-diabetic therapy other than metformin, sulfonylurea, meglitinide and alpha glucosidase inhibitors within the preceding 12 weeks [ie, thiazolidinediones (tzds), dipeptyl peptidase inhibitors (dpp-iv), symlin (pramlintide acetate) and or byetta (exenatide)].
boolean
C0935929 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0038766 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0065880 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1299007 (UMLS CUI [5,2])
C1257987 (UMLS CUI [6])
C1827106 (UMLS CUI [7])
C1174780 (UMLS CUI [8])
C1174779 (UMLS CUI [9])
C1636686 (UMLS CUI [10])
C0167117 (UMLS CUI [11])
Item Group
C0680251 (UMLS CUI)
Exposure to Investigational New Drugs | Exposure to Investigational Medical Device | Study Subject Participation Status
Item
exposure to any investigational medications or devices within the previous 90 days prior to trial entry or participation in another clinical trial while participating in this trial.
boolean
C0332157 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C2346570 (UMLS CUI [2,2])
C2348568 (UMLS CUI [3])
Prescription Drugs | Exception Antidiabetics | Adrenergic alpha-Antagonists allowed | Antihypertensive Agents allowed | Proton Pump Inhibitors allowed | Cholesterol lowering drugs allowed
Item
use of any prescription medication within 90 days prior to screening, other than allowed anti-diabetic therapy, that has not been approved by the pi and sponsor. the use of alpha blockers, antihypertensives, proton pump inhibitors and cholesterol medication as co-medications is allowed throughout the study.
boolean
C0304227 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0935929 (UMLS CUI [2,2])
C0001641 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
C0003364 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
C0358591 (UMLS CUI [5,1])
C0683607 (UMLS CUI [5,2])
C0003277 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])
Improvement Spirometry, before and after bronchodilator | FVC Increase | FEV1 Increase
Item
significant improvement in pre- to post-bronchodilator spirometry (defined as an increase of 12% and 200 ml in either fvc or fev1).
boolean
C2986411 (UMLS CUI [1,1])
C0545456 (UMLS CUI [1,2])
C3714541 (UMLS CUI [2,1])
C0442805 (UMLS CUI [2,2])
C0849974 (UMLS CUI [3,1])
C0442805 (UMLS CUI [3,2])
Serum creatinine raised
Item
serum creatinine above upper limit of normal (uln) as defined by the laboratory
boolean
C0700225 (UMLS CUI [1])
Condition Study Subject Participation Status Inappropriate | Condition Validity Informed Consent Limited | Condition Study Subject Participation Status Impaired
Item
any other condition which, in the opinion of the pi, makes the subject unsuitable for the clinical trial, or could limit the validity of the informed consent and/or impair the subject's ability to participate in the trial.
boolean
C0348080 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2349101 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
C0439801 (UMLS CUI [2,4])
C0348080 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C0221099 (UMLS CUI [3,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial